Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. CSX
7. IBM
8. KNX
9. AMD
10. INTC

Go back to Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
(NASDAQ: DNTH) Delayed: 105.25 +2.49 (2.42%)
Previous Close $102.76    52 Week High $ 
Open $101.03    52 Week Low $ 
Day High $106.56    P/E N/A 
Day Low $100.11    EPS $ 
Volume 304,850